TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04665856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab at a fixed dose of 600 milligrams (mg), administered by intravenous (IV) infusion, every 3 weeks (Q3W) on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atezolizumab
Description: Atezolizumab at a fixed dose of 1200 mg, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab at a fixed dose of 1200 mg, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin administered IV to achieve an initial target area under the concentration time curve (AUC) of 5 mg/mL/min, Q3W on Day 1 of each 21-day cycle for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin administered IV to achieve an initial target area under the concentration time curve (AUC) of 5 mg/mL/min, Q3W on Day 1 of each 21-day cycle for 4 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etoposide
Description: Etoposide 100 mg/m\^2, administered by IV infusion, Q3W on Day 1, 2 and 3 of each 21-day cycle for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 100 mg/m\^2, administered by IV infusion, Q3W on Day 1, 2 and 3 of each 21-day cycle for 4 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tiragolumab Matching Placebo
Description: Matching placebo, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
Study: NCT00066430

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: infrared photocoagulation therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrared Coagulator
Description: IRC treatment of up to 3 HGAIN lesions at baseline (study initiation). A second IRC treatment may be administered for recurrent lesions at the 3 month visit.
Study: NCT02523222

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 40% Dextrose gel
Description: 40% dextrose gel will be rubbed into the hypoglycemic infant's buccal mucosa at a dose of 0.5ml/kg.
Study: NCT04073810

Intervention type: DIAGNOSTIC_TEST
Intervention: PET imaging
Description: Coronary 68Ga-DOTATATE PET-MRI or PET-CT at baseline and 3 months

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary CT angiography
Description: CTCA at baseline and 2 years

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Cardiac MRI at 1 year
Study: NCT01435655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis
Description: tafamidis meglumine 20 mg QD
Study: NCT02030730

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Triple P Seminar Series
Description: The intervention was delivered by the researcher and an accredited TripleP practitioner. The seminars took place in a conference room located within a bookshop. The seminars were re-offered for parents who could not attend the scheduled day.
Study: NCT05446610

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermented product of Pleurotus eryngii mushroom
Description: I Stimulation of human colonic biopsies with the fermented product of Pleurotus eryngii mushroom
Study: NCT01915576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1125976
Description: Oral administration once daily. Starting dose is 10 mg and will be escalated depending on any dose-limiting toxicities

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1125976
Description: Oral administration twice daily. Starting dose is 40mg twice daily and will be escalated depending on any dose-limiting toxicities

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1125976
Description: Oral administration of the defined MTD which shows optimal safety, PK profile, PD target inhibition and preliminary efficacy (once daily or twice daily) in different patient groups
Study: NCT01870388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study: NCT02390934

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radium 223
Study: NCT00893399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin (Mylotarg)
Description: Induction Cycle 1, 2: GO 3mg/m² by intravenous infusion (IVI) on day 1 (total dose 3 mg/m2). Start after etoposide IVI. No dose reduction is foreseen in elderly (\> 60 yrs) patients.~Consolidation 1: GO 3mg/m² by intravenous infusion (IVI) on day 1 (total dose 3 mg/m2). Start after first dose of high-dose cytarabine. No dose reduction is foreseen in elderly (\> 60 yrs) patients.~For all patients experiencing prolonged thrombocytopenia CTC-Grade 3/4 during the first or second induction therapy, which occurs for more than day 35 after start of the cycle, the further cycles of therapy will be administered without Gemtuzumab ozogamicin.~Consolidation 2, 3: no GO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard chemotherapy
Description: Idarubicin, Etoposide, Cytarabine, ATRA, Pegfilgrastim

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard chemotherapy
Description: Idarubicin, Etoposide, Cytarabine, ATRA, Pegfilgrastim
Study: NCT06259383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: 3-day 1 daily dose of 400 μg/kg oral ivermectin
Study: NCT01003925

Intervention type: BEHAVIORAL
Intervention: Standard of care for osteoarthritis treatment
Description: Standard of care educational materials to inform patients about choices for knee pain.

Intervention type: BEHAVIORAL
Intervention: Conjoint Analysis for Osteoarthritis
Description: Conjoint Analysis computer software to inform patients about choices for knee pain.
Study: NCT01170416

Intervention type: OTHER
Intervention: 12-lead body surface mapping
Description: An average of 20 distinct left ventricular sites will be mapped using 12-lead body surface mapping electrodes and recorded for 15 seconds, then sent to a computer for further analysis.

Intervention type: OTHER
Intervention: 12-lead body surface mapping
Description: An average of 20 distinct left ventricular sites will be mapped using 12-lead body surface mapping electrodes and recorded for 15 seconds, then sent to a computer for further analysis.

Intervention type: OTHER
Intervention: 12-lead body surface mapping
Description: An average of 20 distinct left ventricular sites will be mapped using 12-lead body surface mapping electrodes and recorded for 15 seconds, then sent to a computer for further analysis.

Intervention type: OTHER
Intervention: 12-lead body surface mapping
Description: An average of 20 distinct left ventricular sites will be mapped using 12-lead body surface mapping electrodes and recorded for 15 seconds, then sent to a computer for further analysis.
Study: NCT00968435

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bevacizumab, cisplatin, cetuximab, radiation therapy
Description: Patients will receive intensity-modulated radiation therapy (IMRT) in once-daily fractions. A total dose of 70Gy is planned for the primary tumor site over approximately 33 treatment days. Day 1 will refer to the first day of radiation therapy. Concurrent with radiation therapy, patients will receive cisplatin (50 mg/m2 IV on Days 1, 2 and 22, 23) and bevacizumab (15 mg/kg IV on Days 1 and 22). Cetuximab will be administered according to the Bonner regimen (4),with a loading dose approximately 7 days prior to the start of radiation therapy (400 mg/m2 IV once, on approximately Day minus 7), followed by weekly cetuximab infusions (250 mg/m2 IV weekly X 7 infusions) until the completion of radiation therapy.
Study: NCT01919359

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multizyme Cellular Vitality Cyruta Plus SHEP

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Multizyme Cellular Vitality Cyruta Plus SHEP
Study: NCT01970852

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard tablet computer
Description: No special enhancements or links to personal health information.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced tablet computer
Description: Tablet computer with personalized access to data from the patient's electronic health record.
Study: NCT04524598

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Limbix Spark
Description: The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: The Psychoeducation program is divided into 5 lessons. Each lesson covers a different topic about depression.
Study: NCT02491021

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation Class
Description: A 6 week programme of exercise and education in an out patient setting
Study: NCT03985852

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Directed Standard of Care
Description: The pre-test genetic counseling visit will be conducted through access to an automated genetics education assistant accessed through the patient portal. The automated approach will address all the components of the pre-test counseling and contains content designed by the genetic counselors at the University of Utah and NYU. Patients will have the option to contact genetic counselors through the patient portal, by phone, or in person but this will not be required. All results will be reviewed by a genetic counselor. Negative results will be returned by the automated genetics education assistant. Genetic counselors will return results for pathogenic variants and variants of uncertain significance via phone.
Study: NCT02608697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT04596631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Oral semaglutide treatment for 52 weeks. All participants will be dose-escalated to an individual maximum tolerated dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Placebo treatment for 52 weeks.
Study: NCT03002064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: 5-fluorouracil 3750mg per square metre, civ 120 hours every 3 weeks till progression or at most 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin: 60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin: 60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles
Study: NCT00859651

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Cholecalciferol is a vitamin D3. Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body. Cholecalciferol is used to treat or prevent many conditions caused by a lack of vitamin D.~Cholecalciferol will be available in gel capsule form at 10,000 IU (0.25 mg cholecalciferol) each.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Cholecalciferol is a vitamin D3. Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body. Cholecalciferol is used to treat or prevent many conditions caused by a lack of vitamin D.~Cholecalciferol will be available in gel capsule form at 10,000 IU (0.25 mg cholecalciferol) each.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo capsule
Description: Matching placebo capsules
Study: NCT02568631

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: serious game JeStiMulE
Description: The objective of JeStiMulE players will be ending the game after a learning period and two playing periods (with emotional words and idioms, which include three modules each). The session ends when the module is completed, which is approximately one hour per module, or 6 sessions of play.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control video game
Description: The patients will play 6 sessions of one hour with the control video game
Study: NCT00451165

Intervention type: PROCEDURE
Intervention: laparoscopic colorectal surgery
Description: laparoscopic colorectal surgery

Intervention type: PROCEDURE
Intervention: laparoscopic colorectal surgery
Description: laparoscopic colorectal surgery
Study: NCT03654131

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MWA
Description: Patients are allocated to one of the two arms in a 1:1 randomization

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT
Description: Patients are allocated to one of the two arms in a 1:1 randomization
Study: NCT02608697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Study: NCT03407690

Intervention type: OTHER
Intervention: nasal swab
Description: collection of nasal swab to allow carriage of pneumococci to be assessed
Study: NCT00775814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan and Hydrochlorothiazide
Description: Candesartan 8 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for 2 weeks; increased to Candesartan 16 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide (HCT)
Description: Candesartan placebo-matching tablets and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 24 weeks.
Study: NCT01806584

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SRM003
Description: One time implant (3 SRM003 pieces) on surgery day.

Intervention type: OTHER
Group type: OTHER
Intervention: Participating Site's standard practice
Description: Subjects will receive sites' standard practice treatment during the surgical procedure
Study: NCT01445808

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychodynamic Motivation and Training Program (PMT)
Description: The Psychodynamic Motivation and Training Program (PMT) is a psychodynamic stepped care approach. Depending on the individual needs PMT consists of 3 to 8 sessions of individual psychodynamic psychotherapy. If appropriate session 4 - 8 may be conducted by a nurse. PMT targets the mental and external barriers to improve physical activity by focusing on affects, interpersonal relations and maladaptive self- and other representations. PMT will be offered in addition to +Ex.
Study: NCT03492762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cu-DOTA-ECL1i
Description: Radiolabeled probe called Cu-DOTA-ECL1i that recognizes CCR2 and propose to image CCR2 in the lung to ultimately guide diagnosis and therapy.
Study: NCT01445808

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Advice in Exercise Training (+Ex)
Description: Advice in Exercise Training consists of one individual session of advice in exercise training based on the results of the spiroergometry.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual (TAU)
Description: Usual care by family doctor, cardiologist
Study: NCT01807650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleogel-S10, non-adhesive wound dressing
Description: 1 cm or 100 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28

Intervention type: DEVICE
Group type: OTHER
Intervention: Non-adhesive wound dressing only
Description: Soft silicone faced polyurethane foam dressing such as Mepilex® only every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28
Study: NCT03904030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation with or without Anti-Gravity Treadmill
Description: The study will include patients with grade III-IV primary knee osteoarthritis. The investigators will take 27 patients to the both groups. The investigators will look after more specifically the anti-gravity treadmill rehabilitation and traditional rehabilitation after arthroplasty. Follow-up is one year. Functional tests will be made and questionnaires will be given to the patients before operation and after operation. After 6 to 8 weeks, 4 months and 12 months of operation questionnaires will be fil up again. After six month the investigators will send a questionnaire and there will be asked possible rehabilitation sessions, use of drugs and possible complications after knee arthroplasty.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation with or without Anti-Gravity Treadmill
Description: The study will include patients with grade III-IV primary knee osteoarthritis. The investigators will take 27 patients to the both groups. The investigators will look after more specifically the anti-gravity treadmill rehabilitation and traditional rehabilitation after arthroplasty. Follow-up is one year. Functional tests will be made and questionnaires will be given to the patients before operation and after operation. After 6 to 8 weeks, 4 months and 12 months of operation questionnaires will be fil up again. After six month the investigators will send a questionnaire and there will be asked possible rehabilitation sessions, use of drugs and possible complications after knee arthroplasty.
Study: NCT04781361

Intervention type: DRUG
Intervention: Intravenous isotonic fluid - NaCl 131-154 mmol/L in 5% dextrose
Description: Isotonic group will be given fluids containing 131-154 mmol/L Sodium Chloride

Intervention type: DRUG
Intervention: Intravenous Hypotonic fluid- Sodium Chloride < 130 mmol/L
Description: Hypotonic group will be given fluids containing lower than 130 mmol/L :~Dextrose 5% in 0.2% Sodium Chloride, or Dextrose 5% in 0.33 % Sodium Chloride,or Dextrose 5% in %0.45 Sodium Chloride, or Intravenous fluid containing Sodium Chloride \< 130 mmol/L
Study: NCT04798443

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: subureteral endoscopic Injection of Dextranomer/Hyaluronic acid (Dexell)
Description: The subureteral endoscopic injection was done under general anesthesia. the investigators used the subureteral injection technique (STING), as described by O'Donnell and Puri. The volume of Dexell was injected until ureteral orifice collapse in all patients. The needle was held for 30 s.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open ureteral reimplantation (Lich-Gregoir)
Description: The juxtavesical ureter is dissected by open surgery and a submucosal groove is created extending laterally from the ureteral hiatus along the course of the ureter. The ureter is placed in the groove and the detrusor is closed over the ureter with ureteric stent fixation for 21 days. the surgical wound is closed in layers. Urethral catheter for bladder drainage for 3-5 days.
Study: NCT02609646

Intervention type: DRUG
Intervention: Linezolid
Description: Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.

Intervention type: DRUG
Intervention: Meropenem
Description: Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.

Intervention type: DRUG
Intervention: Piperacillin-tazobactam combination product
Description: Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.

Intervention type: DRUG
Intervention: Vancomycin
Description: Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
Study: NCT04444635

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Anterior Plan Block+ Fentanyl infusion
Description: After induction of anesthesia, the patients will be put on the lateral position with the diseased side up. A linear ultrasound transducer will be placed in a sagittal plane over the mid-clavicular region of the thoracic cage.~Then counting down ribs till the fifth rib will be identified in the mid-axillary line. The following muscles will be identified overlying the fifth rib: the latissimus dorsi (superficial and posterior),teres major (superior) and serratus muscles (deep and inferior). Under complete sterile conditions, the needle (25 G needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus anterior muscle. Then, 2 mg/kg of 0.25% bupivacaine will be injected with continuous ultrasound guidance. In addition to continuous fentanyl infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Continuous fentanyl infusion throughout the surgical procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Continuous fentanyl infusion throughout the surgical procedure.
Study: NCT04539314

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacain
Description: We will carry out the TAP block using 0.5 ml/ kg bupivacaine 0.25%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine o.5 μg
Description: We will carry out the TAP block using using 0.5 ml/ kg bupivacaine 0.25% with dexmedetomidine 0.5 μg / kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine 1 μg
Description: We will carry out the TAP block using using 0.5 ml/ kg bupivacaine 0.25% with dexmedetomidine 1 μg / kg
Study: NCT01905644

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perineal ultrasound
Description: Perineal ultrasound will be used after delivery to help detect anal sphincter ruptures.
Study: NCT00740558

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Activator methods technique
Description: Chiropractic adjustment by a manually assisted mechanical force

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Activator methods technique
Description: Chiropractic adjustment by a manually assisted mechanical force